Patents
US 12618850 B2: Methods for analyzing AAV capsid proteins
- Granted
- 2026-05-05
- Filed
- 2020-12-30 application 17782472
- Type
- Utility · 17 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
Provided are methods to characterize the VP1, VP2 and VPS capsid proteins in an adeno-associated virus (AAV) particle using liquid chromatography mass spectrometry, and/or ultraviolet (UV)-visible spectroscopy. The methods generally include the steps of (a) subjecting an AAV particle to liquid chromatography to denature and then separate the VP1, VP2 and VPS capsid proteins, and (b) subjecting the separated VP1, VP2 and VPS capsid proteins produced in step (a) to UV and mass spectrometry to determine the ratio and masses of the VP1, VP2 and VPS capsid proteins in the AAV particle. In another aspect, the disclosure provides an AAV composition comprising a post-translation modification. The disclosure also provides methods for characterizing the purity of AAV compositions using liquid chromatography mass spectrometry.
Source: PTBLXML, file of 2026-05-05 (ipgb20260505.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Sarepta Therapeutics, Inc. 126 patents | US company or organization | Cambridge, MA | Sarepta Therapeutics, Inc. Form D issuer EXACT high confidence: identical full name and state SAREPTA THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally | PTBLXML, file of 2026-05-05 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Kunal Daud | Cambridge, MA | PTBLXML, file of 2026-05-05 | ||
| Ju Li | Cambridge, MA | PTBLXML, file of 2026-05-05 | ||
| Uditha Dealwis | Cambridge, MA | PTBLXML, file of 2026-05-05 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| G01N | Investigating or analysing materials by determining their chemical or physical properties | G01N33/6848 | PTBLXML, file of 2026-05-05 |
| C07K | Peptides | C07K14/005 | PTBLXML, file of 2026-05-05 |
| C12N | Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media | C12N2750/14122 | PTBLXML, file of 2026-05-05 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2025-05-07 | Security interest Security interest Security interest | SAREPTA THERAPEUTICS, INC. signed 2025-02-13 | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT CHICAGO, IL | 71218/445 | PASDL, file of 2026-10-15 |
| 2025-02-11 | Assignment Assignment of assignor's interest | DAUD, KUNAL signed 2020-02-28 LI, JU signed 2020-02-28 DEALWIS, UDITHA signed 2020-02-28 | SAREPTA THERAPEUTICS, INC. CAMBRIDGE, MA | 70176/573 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.